In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.

The European Region is a global vaccine leader, boasting a “strong research ecosystem” and a competitive market, expected to achieve a volume of €16.32 billion by 2029. Through efforts to keep pace with the “unprecedented acceleration” of life science innovation, the landscape attracts investment and political support as leaders recognise the value of vaccination as a cost-effective intervention and a means of demonstrating health leadership.

In a real-world study from Ontario, researchers confirmed that a single dose of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine offers 58% protection against mpox infection.

Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.

Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women.  

Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance.

A recent study published in Science Advances highlights significant and unequal declines in life expectancy in India during the COVID-19 pandemic.

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) hosted its 2024 Global Congress in Barcelona, continuing its tradition of presenting high-quality data and fostering insightful discussions.

The World Health Organization (WHO) has introduced updated guidelines for managing chronic hepatitis B, with the goal of enhancing testing, diagnosis and treatment, revealed at the 2024 Asian Pacific Conference for the Study of Liver Disease. These guidelines expand recommendations to include teenagers and emphasize patient choice and aim to simplify treatment decisions and improve access to care, particularly in resource-limited areas, by allowing treatment initiation without extensive viral testing.